Clasp Therapeutics to Present Preclinical Data Evaluating Novel T Cell Engager Targeting p53 Mutant Solid Tumors

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Maze Therapeutics Initiates Phase 1 First-in-Human Trial Evaluating MZE782 as a Potential Treatment for Chronic Kidney Disease

Septerna Presents New Preclinical Data at ASBMR 2024 Highlighting Therapeutic Potential of Oral Small Molecule Parathyroid Hormone 1 Receptor (PTH1R) Agonists for Hypoparathyroidism

In Vivo Nonclinical Evaluation of Activity and Safety of a T Cell Receptor Engineered Regulatory T Cell Therapy for MS Progression Independent of Relapse Activityabta

Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer

Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies

Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis

Clasp Therapeutics Receives DC Inno Fire Award

MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor

Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officerf

Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development

Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors

Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D. as Chief Executive Officer

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures

CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet

Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis

AbbVie Acquires Celsius Therapeutics

MOMA Therapeutics Appoints Marc Ballas, M.D., as Head of Clinical Development, and Adam Thomas as Chief People & Experience Officer

Seaport Therapeutics Appoints Seasoned Executives to Management Team

Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Rapport Therapeutics Announces Pricing of Initial Public Offeringrappo

ARTBIO and Oslo University Announce Collaboration to Advance the Research and Development of Alpha Radioligand Therapies

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

Flare Therapeutics to Present at Goldman Sachs 45^th Annual Global Healthcare Conference

Septerna Presents Preclinical Data at ENDO 2024 Highlighting Therapeutic Potential of its GPCR Drug Discovery Platform

CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

FogPharma and ARTBIO Announce Collaboration to Co-Develp Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer

CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease

Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) As Chief Executive Officer

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Flare Therapeutics Presents Data At AACR 2024 Annual Meeting Characterizing PPARG-Derived Immune Cell Patterns in Urothelial Cancer Patients After Anti-PD1 Therapy

Tango Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635( C) (4)

Pliant Therapeutics to Participate in Upcoming Investor Events

Leading Clinical Research Innovator, Amy Abernethym M.D., Ph.D., Joins insitro Board of Directors

Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference